mRNA vaccines may look simple from the outside, but moving them from a promising laboratory process to millions of reliable doses is a very different challenge.
The difficult part is not only producing the mRNA. Companies must manage in-vitro transcription, purification, lipid nanoparticle (LNP) formulation, sterile filling, packaging, quality testing and cold-chain handling without losing consistency as production increases.
That is why specialized CDMOs have become important partners for vaccine developers.
Lonza: One of the Most Proven Names in mRNA Scale-Up
Lonza remains one of the strongest names to consider when the priority is large-scale mRNA manufacturing.
Its relationship with Moderna is probably the best-known example. In 2020, the two companies signed a 10-year collaboration designed to enable production of up to 1 billion doses per year of Moderna’s COVID-19 vaccine.
Lonza later expanded the network, including additional manufacturing capacity in Switzerland and the Netherlands.
Today, the company offers mRNA/LNP manufacturing, technology transfer, process development and sterile vial filling, supporting the transition from clinical production toward commercial supply.
Thermo Fisher Brings Scale and Fill–Finish Together
Thermo Fisher Scientific is particularly attractive when a developer wants broad manufacturing support rather than only mRNA drug-substance production.
Its mRNA workflow covers everything from template production and mRNA synthesis through purification, analytics, LNP formulation and fill–finish.
The company’s relationship with Moderna is another useful benchmark. In 2022, Thermo Fisher announced a 15-year strategic collaboration with Moderna for dedicated large-scale US manufacturing, including aseptic fill–finish, inspection, labeling and final packaging.
The agreement specifically included both liquid and lyophilized filling, which is important for developers considering different product formats.
Catalent: Strong Option for Integrated mRNA Manufacturing
Catalent is another company worth watching because its capabilities cover a large part of the mRNA production chain.
The company provides services spanning plasmid DNA, IVT, LNP formulation and fill–finish. Catalent reports more than 60 mRNA IVT batches manufactured and released to date.
Its Madison, Wisconsin facility includes cGMP manufacturing space with 1–50 L single-use IVT reactors and 2–35 L glass reactors.
Catalent also operates a global fill–finish network capable of handling liquid and lyophilized vials as well as prefilled syringes, giving developers flexibility as programs move toward clinical and commercial supply
Samsung Biologics Is Building a Broader mRNA Platform
Samsung Biologics has also expanded into mRNA manufacturing, with services covering process development, analytical testing, characterization and cGMP production.
Its mRNA platform supports 0.1 L to 200 L single-use IVT batch capacity, giving developers a pathway for moving from smaller development batches toward larger production.
The company also offers drug-product fill–finish, inspection, packaging and cold-chain capabilities, including storage down to -70°C for temperature-sensitive products.
A Simple Comparison
| Company | mRNA scale-up | Fill–finish | Notable capability |
|---|---|---|---|
| Lonza | Strong | Yes | Moderna manufacturing partnership; global mRNA network |
| Thermo Fisher Scientific | Strong | Yes | End-to-end workflow and dedicated Moderna capacity |
| Catalent | Strong | Yes | 60+ released mRNA IVT batches |
| Samsung Biologics | Up to 200 L IVT | Yes | Integrated mRNA/LNP and cold-chain capabilities |
What Should Vaccine Developers Look For?
Choosing an mRNA manufacturing partner should not come down to reactor size alone.
The more important question is whether the CDMO can maintain product quality during scale-up, transfer the process smoothly, handle LNP formulation, perform reliable sterile filling and support regulatory documentation.
For mRNA vaccines, fill–finish also deserves special attention because the final product can be sensitive to temperature, handling and formulation conditions.
A company may have excellent mRNA production capabilities but still create a bottleneck if its filling, inspection, packaging or cold-chain capacity cannot keep pace.
The Real Advantage Is an End-to-End Partner
The strongest CDMOs are increasingly trying to remove the gaps between development and commercial manufacturing.
Lonza brings deep experience in mRNA scale-up, Thermo Fisher combines mRNA manufacturing with dedicated fill–finish capabilities, Catalent offers an integrated mRNA-to-drug-product pathway, and Samsung Biologics is building scale across both drug substance and drug product.
For vaccine developers, the practical goal is simple: move from laboratory batches to consistent commercial supply without having to rebuild the manufacturing process at every stage.
That is ultimately what separates a useful manufacturing partner from a company that simply provides production capacity.
Important Links
We analyze your business, understand your challenges, and provide solutions built around your growth goals. Contact us now: https://www.towardshealthcare.com/contact-us
Get a dashboard built around your niche; with the exact data and insights you need. Email: us at [email protected]
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium